Pfizer, Inc. (NYSE:PFE) – Equities researchers at Leerink Swann lifted their FY2017 earnings per share (EPS) estimates for shares of Pfizer in a research note issued on Tuesday. Leerink Swann analyst S. Fernandez now forecasts that the biopharmaceutical company will post earnings per share of $2.60 for the year, up from their previous estimate of $2.55. Leerink Swann also issued estimates for Pfizer’s FY2018 earnings at $2.66 EPS, FY2019 earnings at $2.70 EPS and FY2020 earnings at $2.73 EPS.
A number of other brokerages have also recently issued reports on PFE. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank restated a “hold” rating and set a $36.00 price objective (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Deutsche Bank AG set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.35.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The firm had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. During the same quarter last year, the business posted $0.61 EPS. The company’s revenue was up .9% on a year-over-year basis.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.61%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is currently 79.01%.
In other Pfizer news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Insiders have sold 389,621 shares of company stock worth $13,298,598 over the last ninety days. Insiders own 0.06% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. raised its position in Pfizer by 1.3% during the third quarter. Principal Financial Group Inc. now owns 14,802,058 shares of the biopharmaceutical company’s stock worth $528,433,000 after acquiring an additional 186,790 shares in the last quarter. Access Financial Services Inc. raised its position in shares of Pfizer by 14.7% in the third quarter. Access Financial Services Inc. now owns 44,259 shares of the biopharmaceutical company’s stock valued at $1,580,000 after purchasing an additional 5,672 shares during the period. Oregon Public Employees Retirement Fund raised its position in shares of Pfizer by 1.2% in the third quarter. Oregon Public Employees Retirement Fund now owns 1,652,936 shares of the biopharmaceutical company’s stock valued at $59,010,000 after purchasing an additional 19,989 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI raised its position in shares of Pfizer by 2.8% in the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 224,950 shares of the biopharmaceutical company’s stock valued at $8,031,000 after purchasing an additional 6,088 shares during the period. Finally, Blackhill Capital Inc. raised its position in shares of Pfizer by 9.8% in the third quarter. Blackhill Capital Inc. now owns 511,201 shares of the biopharmaceutical company’s stock valued at $18,250,000 after purchasing an additional 45,773 shares during the period. 69.01% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.